IBRX
NASDAQImmunityBio Inc.
News · 26 weeks840%
2025-12-142026-06-07
Mix3290d
- Other20(63%)
- SEC Filings8(25%)
- Insider2(6%)
- Analyst1(3%)
- Earnings1(3%)
Latest news
25 items- PRThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers. SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. GT Biopharma, Inc. (NASDAQ:GTBP) has now advanced three TriKE® candidates into the clinic over time --- GTB-3550, GTB-3650 and GTB-5550 --- though its curr
- INSIDERDirector Simon Barry J. sold $165,306 worth of shares (23,033 units at $7.18) as part of a pre-agreed trading plan, decreasing direct ownership by 0.81% to 2,827,788 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- PRThe Multi-Billion-Dollar Search for Better Glioblastoma TreatmentsDENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad
- PRImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC) ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively evaluate ANKTIVA® (nogapendekin alfa inbakicept-pmln), the company's IL-15 receptor agonist immunotherapy d
- PRThe $13 Million Company Teaching the Immune System to Hunt CancerIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
- PRImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary disease FDA noted in its filing communication that the supplemental BLA accepted for review was based on the additional scientific data ImmunityBio provided at the Agency's request, detailing the overlapping features of papillary and CIS disease to determine adequate justification to allow for the expansion of the already approved indication of ANKTIVA with BCG to include the treatment of patients with BCG unresponsive NMIBC with papillary tumors During the FDA workshop held on May 18, 2026, panelists stated that CIS and papillary disease arise from the same cancer induci
- PRThree TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc. (NASDAQ:IBRX), INmune Bio, Inc. (NASDAQ:INMB)SAN FRANCISCO, May 19, 2026 /CNW/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autol
- PRImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026NAI+BCG versus Nadofaragene Results: NAI+BCG treated patients were twice as likely to achieve a complete response (CR) at any point of the study versus nadofaragene firadenovec-vncg in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary disease Median duration of CR with NAI+BCG was more than twice that observed with nadofaragene firadenovec-vncg (22.1 versus 9.7 months) NAI+BCG reduced cystectomy risk by 60% versus nadofaragene NAI+BCG versus TAR-200 Results: NAI+BCG demonstrated numerically higher 12-month CR rates and fewer treatment-related adverse events of any grade than TAR-200 (61.7% versus 83.5%) ImmunityBio
- SECImmunityBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035Five issued U.S. patents cover the combination of ImmunityBio's IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer treatment, with terms extending through at least 2035 Claims cover methods of treating non-muscle invasive bladder cancer (NMIBC) including BCG-naïve disease, defined-dose pharmaceutical compositions matching the approved NAI + BCG intravesical regimen, and two-vial commercial kits Portfolio reinforces ImmunityBio's IL-15 receptor agonist plus BCG position as the Company executes its exclusive U.S. Tokyo-172 BCG supply agreement with Japan BCG Laboratory and continues to develop Recombinant BCG (rBCG) to enhance USA su
- PRImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United StatesPositive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tokyo strain of BCG (Tokyo-172 BCG) versus TICE BCG in BCG-naïve high-grade non-muscle invasive bladder cancer ImmunityBio to serve as sole U.S. Biologics License Application applicant for the Tokyo strain of BCG and plans to engage with U.S. Food and Drug Administration (FDA) on regulatory pathway to address the over decade long unresolved BCG shortage in the United States Agreement positions ImmunityBio with second potential BCG source to help address U.S. supply needs Through ImmunityBio's ongoing partnership with Serum Institute of I
- PRMiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical ValidationRandomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung diseaseNon-dilutive collaborations expand MiNK's platform and potentiate meaningful commercial revenue potential, while preserving focus on lead clinical programsCompany continues disciplined execution with reduced operating burn and focused advancement of high-priority programsNew clinical data to be presented at the ATS conference on May 20, 2026 NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, I
- PRSolid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhaseMarket News Updates News Commentary Breakthrough immunotherapies, ADCs, and precision oncology platforms continue driving major investor attention across the global cancer treatment sectorNEW YORK, May 14, 2026 /CNW/ -- Momentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across some of the hardest-to-treat cancers. From lung and breast cancer to colorectal, ovarian, and pancreatic cancers, drug developers are making real progress with next-generation immunotherapies, targeted treatments, and antibody-drug conjugates (ADCs). What's getting the industry excited is that many of these newer therapies are showi
- SECSEC Form 10-Q filed by ImmunityBio Inc.10-Q - ImmunityBio, Inc. (0001326110) (Filer)
- SECImmunityBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 MillionQ1 2026 Revenue Growth with Continued Strong Sales Momentum: $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 and up 15% from Q4 2025 ANKTIVA® Unit Growth: 168% increase in unit sales volume in Q1 2026 compared to Q1 2025 ANKTIVA Regulatory Update: ANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries, including first approval in Asia by the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People's Republic of China. Commercial availability achieved within two months of announcing MENA partnership with Biopharma and Cigalah Healthcare. Cash P
- PRImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual MeetingCross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide important context, particularly in the absence of head-to-head data, highlighting its efficacy, durability, and safety in patients with CIS ± papillary disease and informing treatment selection and sequencing within current paradigms Exploration of intravesical recombinant BCG (rBCG) in BCG-naïve patients points to continued innovation and potential expansion into earlier lines of care Updates on company's efforts to expand BCG access and on the status of randomized controlled BCG Naïve registrational trial ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today a
- SECSEC Form DEF 14A filed by ImmunityBio Inc.DEF 14A - ImmunityBio, Inc. (0001326110) (Filer)
- SECSEC Form DEFA14A filed by ImmunityBio Inc.DEFA14A - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA PartnershipANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer Commercial availability achieved within two months of announcing MENA partnership with Biopharma and Cigalah Healthcare First patients to be dosed have been identified and will soon receive initial ANKTIVA treatment ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA® (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia. Initial patients have been identified for treatment across both approved bladder and lung cancer indications in the Kingdom: In combination with Bacillus Calmette-Guérin
- SECImmunityBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable SecuritiesPreliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 Consistent quarter-over quarter revenue growth since commercial launch, reflecting continued adoption of ANKTIVA® by U.S. urologists Full-year 2025 net product revenue of $113 million, a 700% increase over full-year 2024, as reported in the Company's Form 10-K ANKTIVA Unit Growth: 168% increase in unit sales volume in Q1 2026 compared to Q1 2025 ANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries NCCN Clinical Practice Guidelines updated in March 2026 to include ANKTIVA plus
- SECImmunityBio Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising ComplianceCompany initiated a comprehensive review of promotional materials and is implementing enhanced advertising compliance measures, including expanded promotional review protocols, executive training, and external regulatory oversight Company has removed the identified podcast from its corporate website and formally requested its removal from all third-party hosting platforms Company confirmed that the television advertisement cited in the FDA correspondence was never broadcast, aired, or disseminated to the public ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced it has submitted a comprehensive response to the U.S. Food and Drug Administration (FDA
- INSIDERSEC Form 4 filed by Soon-Shiong Patrick4 - ImmunityBio, Inc. (0001326110) (Issuer)
IBRX FAQ
7 questionsWhat does ImmunityBio Inc. do?
ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer...Where does IBRX stock trade?
ImmunityBio Inc. (IBRX) is listed on NASDAQ.What sector and industry is IBRX in?
ImmunityBio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did ImmunityBio Inc. go public?
ImmunityBio Inc. (IBRX) completed its IPO in 2015.What are analysts saying about IBRX?
ImmunityBio Inc. has had 6 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $1300.00 price target on 2026-03-12. Recent price targets range from $400.00 to $1300.00.What companies are similar to IBRX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare IBRX side-by-side with any of them on Quantisnow.How can I track IBRX on Quantisnow?
Quantisnow aggregates ImmunityBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IBRX to receive live email and push alerts on every new disclosure.